Differential effects of two different routes of immunization on protection against gram-negative sepsis by a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine in a burned mouse model.
Gram-negative sepsis causes morbidity and mortality in burned patients. To determine whether immunization with core endotoxin (lipopolysaccharide) via one of two routes could protect burned mice from septic death, mice were immunized either three times subcutaneously (SC) or one time intramuscularly (IM) then two times intraperitoneally (IP) with a core-lipopolysaccharide vaccine. Control mice were immunized with either saline or an irrelevant antigen. Postimmunization, mice were immunocompromised with a 15% TBSA flame burn and challenged subeschar with Klebsiella pneumoniae or Escherichia coli. Vaccine immunization improved the survival of both E. coli- and K. pneumoniae-challenged mice when given SC but not when given IM, IP. Postimmunization, total immunoglobulin titers were elevated over preimmune titers, but titers in IM, IP-immunized mice were higher than those in SC-immunized mice. Both isotyping and flow cytometry studies indicated that sera from mice immunized via IM, IP opsonized better than sera from mice immunized via SC. Hence, this vaccine provided route-specific protection of burned mice against gram-negative sepsis; its mechanism of action was not solely dependent upon increased immunoglobulin titers or phagocytosis.
D000818:Animals; D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D002056:Burns / Q000150:complications* / Q000276:immunology; D004195:Disease Models, Animal; D004731:Endotoxins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D004926:Escherichia coli / Q000276:immunology*; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D018805:Sepsis / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination
D001425:Bacterial Outer Membrane Proteins; D004731:Endotoxins; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; C039455:capsular polysaccharide, meningococcal group B; C042058:core endotoxin